3 results match your criteria: "WV (J.I.S.); and Holy Name Medical Center[Affiliation]"
Mitochondrial Metabolic Reprogramming by CD36 Signaling Drives Macrophage Inflammatory Responses.
Circ Res
December 2019
From the Blood Research Institute, Versiti, Blood Center of Wisconsin, Milwaukee (Y.C., W.H., Y.Z., M.L.S., Z.G., W. Cui, S.M., R.L.S.).
Article Synopsis
- Chronic inflammatory diseases, like atherosclerosis, feature persistent proinflammatory macrophages linked to dyslipidemia and oxidative stress, but the exact mechanisms connecting these factors to macrophage activation are not fully understood.
- The study aimed to explore how dyslipidemia and oxidative stress affect macrophage behavior through changes in immunometabolism and assessed potential therapies by targeting specific metabolic pathways.
- Findings indicate that oxidized LDL activates CD36, leading to a shift in mitochondrial metabolism that favors superoxide production over energy generation, resulting in inflammation and structural changes in macrophages that could be targeted for therapeutic purposes.
Relationship of Albuminuria and Renal Artery Stent Outcomes: Results From the CORAL Randomized Clinical Trial (Cardiovascular Outcomes With Renal Artery Lesions).
Hypertension
November 2016
From the Departments of Diagnostic Imaging (T.P.M.) and Medicine (L.D.D.), Rhode Island Hospital, Providence; Alpert Medical School of Brown University, Providence, RI (T.P.M., L.D.D.); Department of Medicine, University of Toledo, OH (C.J.C.); Departments of Statistics (K.M.P., R.B.D, J.M.M.), Medicine (D.E.C.), and Biostatistics (Q.G.), Harvard Clinical Research Institute, Boston, MA; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA (D.E.C.); Department of Mathematics and Statistics, Boston University, MA (R.B.D.); Department of Medicine, University of Michigan, Ann Arbor (K.J.); Department of Radiology, University of Virginia, Charlottesville (A.H.M.); Department of Medicine, University of Texas Health Science Center, San Antonio (W.H.); Department of Medicine, Marshall University, Huntington, WV (J.I.S.); Department of Medicine, Providence Health Care and University of Washington School of Medicine, Spokane (K.R.T.); Department of Medicine, St. Luke's Hospital, Kansas City, MO (D.J.C.); Departments of Pathology (M.S.) and Medicine (A.H.), The University of Minnesota Medical School, Minneapolis; Department of Medicine, Wellmont-Holston Valley Medical Center, Kingsport, TN (D.C.M.); Department of Medicine, Asheville Cardiology Associates, NC (W.B.A.); Department of Medicine, Mayo Clinic, Rochester, MN (S.C.T.); Department of Radiology, Lancaster General Hospital, PA (J.B.); and Department of Medicine, Sunnybrook Research Institute (S.T.), Toronto, Ontario, Canada.
Unlabelled: Randomized clinical trials have not shown an additional clinical benefit of renal artery stent placement over optimal medical therapy alone. However, studies of renal artery stent placement have not examined the relationship of albuminuria and treatment group outcomes. The CORAL study (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) is a prospective clinical trial of 947 participants with atherosclerotic renal artery stenosis randomized to optimal medical therapy with or without renal artery stent which showed no treatment differences (3(5.
View Article and Find Full Text PDFStenting and medical therapy for atherosclerotic renal-artery stenosis.
N Engl J Med
January 2014
From the University of Toledo, Toledo, OH (C.J.C.); Rhode Island Hospital (T.P.M., L.D.D.) and Alpert Medical School of Brown University (T.P.M., L.D.D.) - both in Providence; Harvard Clinical Research Institute (D.E.C., J.M.M., R.B.D.), Beth Israel Deaconess Medical Center (D.E.C.), Massachusetts General Hospital (M.R.J.), Brigham and Women's Hospital (E.F.L.), and Boston University School of Public Health (R.B.D.) - all in Boston; University of Michigan, Ann Arbor (K.J.); University of Texas Health Science Center, San Antonio (W.H.); National Heart, Lung and Blood Institute, Bethesda, MD (D.M.R.); Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); University of Virginia, Charlottesville (A.H.M.); University of Minnesota, Minneapolis (M.S.); Weill Cornell Medical Center, New York (M.R.P.); Providence Sacred Heart Medical Center and University of Washington School of Medicine, Spokane (K.R.T.); Marshall University, Huntington, WV (J.I.S.); and Holy Name Medical Center, Teaneck NJ (J.H.R.).
Background: Atherosclerotic renal-artery stenosis is a common problem in the elderly. Despite two randomized trials that did not show a benefit of renal-artery stenting with respect to kidney function, the usefulness of stenting for the prevention of major adverse renal and cardiovascular events is uncertain.
Methods: We randomly assigned 947 participants who had atherosclerotic renal-artery stenosis and either systolic hypertension while taking two or more antihypertensive drugs or chronic kidney disease to medical therapy plus renal-artery stenting or medical therapy alone.